Eltrombopag
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Purpura, Thrombocytopaenic, Idiopathic
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Trial Timeline
Dec 21, 2010 โ Oct 16, 2020
NCT ID
NCT01416311About Eltrombopag
Eltrombopag is a pre-clinical stage product being developed by Novartis for Purpura, Thrombocytopaenic, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT01416311. Target conditions include Purpura, Thrombocytopaenic, Idiopathic.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04837703 | Pre-clinical | Active |
| NCT05286164 | Phase 2 | UNKNOWN |
| NCT03988608 | Phase 2 | Completed |
| NCT03718533 | Phase 2 | Terminated |
| NCT03664518 | Phase 2 | Completed |
| NCT03524612 | Phase 2 | Completed |
| NCT02877212 | Phase 3 | UNKNOWN |
| NCT02323178 | Phase 1/2 | Completed |
| NCT01703169 | Phase 2 | Completed |
| NCT01715779 | Pre-clinical | Completed |
| NCT01416311 | Pre-clinical | Completed |
Competing Products
20 competing products in Purpura, Thrombocytopaenic, Idiopathic